Literature DB >> 11553862

Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.

M J Gaspar1, I Arribas, M C Coca, M Díez-Alonso.   

Abstract

The prognostic value of preoperative serum levels of carcinoembryonic antigen (CEA), CA 19-9 and CA 72-4 tumor markers was investigated in patients with gastric cancer. Eighty-two patients who underwent surgical resection of gastric cancer were entered in the study. Correlation analyses showed that CA 72-4 was more frequently positive in patients with advanced tumors (p = 0.04), lymph node invasion (p = 0.02), liver metastasis (p = 0.02) and peritoneal involvement (p = 0.03). CA 19-9 was more frequently positive in patients with advanced tumors (p = 0.01) and with serosal (p = 0.04), lymph node (p = 0.008) and peritoneal involvement (p = 0.02). CEA was more frequently positive in patients with liver metastasis (p = 0.03). Low 3-year cumulative survival was significantly associated with elevated serum levels of CA 72-4 (p = 0.004), CA 19-9 (p = 0.001) and CEA (p < 0.001). Age, tumor stage and CA 72-4 provided prognostic information in the multivariate analysis. Patients with elevated serum levels of CA 72-4 showed a 4.2 times higher risk of death than patients with low levels of the marker. Our results suggest that CA 72-4 has prognostic value in gastric cancer, and patients with a high preoperative serum level of CA 72-4 have a greater risk of death due to gastric cancer. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553862     DOI: 10.1159/000050633

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  50 in total

1.  Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.

Authors:  D Arioli; M Pipino; E Boldrini; E Amateis; A Cristani; P Ventura; E Romagnoli; M C De Santis; M L Zeneroli
Journal:  Intern Emerg Med       Date:  2007-07-09       Impact factor: 3.397

2.  High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer.

Authors:  A Ra Choi; Jun Chul Park; Jie-Hyun Kim; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee; Jae Bock Chung
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

3.  Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer.

Authors:  Jiuchang Xiao; Xiaoyan He; Zengyan Wang; Jiying Hu; Fang Sun; Feng Qi; Shugang Yang; Zhenyu Xiao
Journal:  Tumour Biol       Date:  2014-02

4.  Preliminary study on proteomics of gastric carcinoma and its clinical significance.

Authors:  Hong-Gang Qian; Jing Shen; Hong Ma; Hua-Chong Ma; Ya-Hui Su; Chun-Yi Hao; Bao-Cai Xing; Xin-Fu Huang; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

6.  Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer.

Authors:  Qing Wang; Yang Yang; Ya-Ping Zhang; Zhengyun Zou; Xiaoping Qian; Baorui Liu; Jia Wei
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

7.  The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.

Authors:  Minkyu Jung; Hei-Cheul Jeung; Sung Sook Lee; Jun Yong Park; Soojung Hong; Soo Hyeon Lee; Sung Hoon Noh; Hyun Cheol Chung; Sun Young Rha
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

8.  The characteristics of the serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer cases.

Authors:  Noriko Wada; Yukinori Kurokawa; Yasuhiro Miyazaki; Tomoki Makino; Tsuyoshi Takahashi; Makoto Yamasaki; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2016-08-26       Impact factor: 2.549

9.  Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.

Authors:  L C Scott; T R J Evans; J Cassidy; S Harden; J Paul; R Ullah; V O'Brien; R Brown
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.